Repibresib

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameRepibresib
Drug Alias NameVYN-201VYN201TAY-B1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain testis-specific protein inhibitorsBromodomain-containing protein 2 inhibitorsBromodomain-containing protein 3 inhibitors +[4] 
TargetsBromodomain testis-specific proteinBromodomain-containing protein 2Bromodomain-containing protein 3 +[4] 
Therapy Area/IndicationsInflammationVitiligoSkin Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTay Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTay Therapeutics LtdVyne Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationVitiligoSkin Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A